|By PR Newswire||
|August 13, 2014 02:00 PM EDT||
NEW YORK, Aug. 13, 2014 /PRNewswire/ -- Axxess Pharma, Inc. (OTCBB: AXXE) offers products targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma intends to market these products with affordable pricing and widespread availability.
The company has acquired the assets necessary to distribute all of the TAPOUT products line of muscle enhancement line and a complete line of nutraceuticals.
With a plethora of products to market many investors are now waiting to see the revenues. To learn more about the revenue potential a full report on AXXE that includes, potential revenues, and review of current business model, management and analyst summary, can be viewed by using the following link:
Copy and paste to browser may be required.
Once you read our reports written by our team of financial analysts you will understand that we make every effort to provide informative equity research reports for interested parties at no cost.
Our Financial Analysts spend countless hours researching stocks. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges. These reports include a straightforward assessment of the company by a financial analyst who has pledged to remain free of influence when writing research reports.
This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.
Content is researched, written and reviewed on a best-effort basis. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. We do not engage in high frequency trading.
A full disclaimer can be found by viewing the full analyst report.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected]. For any urgent concerns or inquiries please contact us at [email protected].
BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.